Short time guided bone regeneration using beta-tricalcium phosphate with and without fibronectin - An experimental study in rats

Guided bone regeneration using beta-tricalcium phosphate and leucocyte platelet-rich fibrin versus a novel biodegradable urethane composite in critical-size osseous defects in rabbit tibia: Histologic results of a pilot study

BACKGROUND

Insufficient bone volume is a major problem in implant dentistry, which can be counteracted by using guided bone regeneration technique. Among the materials recently tested, synthetic polymers have been recommended as showing excellent biocompatibility and biodegradability.

OBJECTIVE

The aim of this pilot study was to analyze and compare through means of histology the healing of the bone tissue in critical size osseous defects in New-Zealand rabbit tibiae after application of beta-tricalcium phosphate (β-TCP) alone, β-TCP combined with leucocyte platelet-rich fibrin (L-PRF) and an injectable experimental bone cement (EBC) represented by a dual-curable degradable synthetic polymer.

METHODS

Two New-Zealand rabbits were used. Three standardized osseous defects of 5 mm diameter were created in each tibia. Each defect was filled with either β-TCP alone (control), β-TCP combined with L-PRF (test) or with EBC (test). The animals were sacrificed at 25 and 70 days; the tibia samples were removed, fixed in 10 % formaldehyde and stained with AZAN.

RESULTS

While at 25 days β-TCP produced sparse bone formation, at 70 days mature bone formation was visible in all areas of the defect with minimum remaining graft particles; at 25 days, β-TCP combined with L-PRF produced broad areas of bone lamellae, while at 70 days bone tissue formation was limited; at both 25 and 70 days, the EBC was stable and not penetrated by bone cells, while a narrow band of connective tissue could be seen superjacent and inferior to it.

CONCLUSIONS

Among the tested biomaterials, β-TCP was capable of generating bone formation at both healing time-points, while the addition of L-PRF seemed to provide a synergistic effect only in the early phase of bone healing.

Fibronectin in Fracture Healing: Biological Mechanisms and Regenerative Avenues

The importance of extracellular matrix (ECM) proteins in mediating bone fracture repair is evident, and fibronectin (FN) has emerged as a pivotal regulator of this process. FN is an evolutionarily conserved glycoprotein found in all tissues of the body, and functions in several stages of fracture healing. FN acts as a three-dimensional scaffold immediately following trauma, guiding the assembly of additional ECM components. Furthermore, FN regulates cellular behavior via integrin-binding and growth factor-binding domains, promoting downstream responses including cell recruitment, proliferation and differentiation. Due to its diverse functions, the development of FN-based strategies to promote fracture healing is under intense research. In this review, we discuss the recent advancements in utilizing FN-based biomaterials, showing promise in tissue engineering and regenerative medicine applications.

Bone Healing and Regeneration Potential in Rabbit Cortical Defects Using an Innovative Bioceramic Bone Graft Substitute

This study aimed to elucidate the local effect and micro-computed tomographic (μ-CT) assessment following bone implantation of an innovative bioceramic (α-calcium sulfate hemihydrate; α-CSH) on femur lateral condyle cortical bone of rabbit models. The innovative α-CSH bioceramic was synthesized through a green processing technology (microwave irradiation treatment). The bilateral implantation model was performed among 24 New Zealand White rabbits which were divided into three groups based on the type of filling materials: α-CSH, control, and blank. Treatments were performed in defects with 6 mm diameter and 7 mm depth and observed after 2, 4, 8, and 12 weeks. Material reaction and bone formation after implantation were evaluated radiographically and histopathologically. The μ-CT analysis results showed that the degradation of α-CSH and control material was similar at 4 and 8 weeks. The bone volume in the defects indicated the α-CSH increased most in 8 weeks. In histopathological evaluation, the α-CSH group was repaired with lamellar bone and well-grown bone marrow infiltration similar to the control material. Moreover, the α-CSH revealed a faster degradation rate and better healing progress than the control material under the same conditions. Therefore, the α-CSH was confirmed to be useful in promoting osteoconduction and in controlling the resorption rate in bone defects. Further, the innovative α-CSH could be considered as a promising bone substitute for utilization in bone reconstructive therapy in dental and orthopedic fields.